

Quetiapine의 정신분열증에 대한 효능 및 안전성에 관한 개방 연구

이홍식¹ · 강대엽² · 송동호³ · 김영신⁴ · 전덕인³ · 김세주⁴ · 김유석¹ · 안석균¹

연세대학교 의과대학 정신과학교실,¹ 의료법인 용인정신병원,²
국민건강보험공단 일산병원 정신과,³ 한림대학교 의과대학 정신과학교실⁴

ABSTRACT

Open Clinical Trial to Assess the Efficacy and Safety of Quetiapine in Patients of Schizophrenia

Hong-Shick Lee, MD,¹ Dae-Yeob Kang, MD,² Dong-Ho Song, MD,³ Young-Shin Kim, MD,⁴
Duk-In Jon, MD,³ Se-Joo Kim, MD,⁴ You-Seok Kim, MD¹ and Suk-Kyoon An, MD¹

¹Department of Psychiatry, Yonsei University College of Medicine, Seoul,

²Medical Corporation Yong-in Mental Hospital, Yongin,

³Ilsan Hospital, National Health Insurance Corporation, Ilisan,

⁴Department of Psychiatry, Hallym University College of Medicine, Seoul, Korea

Objective : The efficacy, tolerability and safety of quetiapine in schizophrenia patients diagnosed by the diagnostic criteria of schizophrenia of the Diagnostic Statistical Manual 4th edition was studied in psychiatric department of 4 hospital in Korea. **Methods :** Sixty-four patients (male 31, female 33 ; age 34.2 ± 10.4 years ; illness duration 8.1 ± 8.3 years) who showed acute exacerbation, partial response, or intolerable adverse event to previous antipsychotic drugs were recruited. Doses of quetiapine were adjusted to maximize efficacy and minimize adverse events. Efficacy was assessed by the Brief Psychiatric Rating Scale (BPRS) and Clinical Global Impression (CGI) scale. Tolerability and safety were assessed by reports of adverse events, clinically significant abnormal laboratory values and changes from the baseline to week 8 in the Abnormal Involuntary Movement Scale (AIMS) and Simpson-Angus total score as index of extrapyramidal symptoms (EPS). **Results :** Fiftythree patients completed the 8 weeks trial. The clinical symptoms indexed by BPRS were significantly improved (baseline score= 37.9 ± 13.0 , score at the end= 24.3 ± 13.6 ; $F=41.5$, $d.f.=2.4$, $p=0.000$). The CGI score of severity of illness was also significantly reduced (baseline score= 4.7 ± 1.1 , score at the end= 3.6 ± 1.2 ; $F=27.6$, $d.f.=2.2$, $p=0.000$). The frequencies of the worsening of AIMS and Simpson-Angus scores at the end of study were 7.5% and 4.2%, respectively. The most common adverse events of at least moderate intensity were EPS (9.3%), constipation (6.3%), and sedation (4.7%). **Conclusion :** The results of this study suggest that quetiapine is effective, may have a favorable EPS, and has overall safe tolerability in the patients with schizophrenia, and schizophreniform disorder. (Korean J Psychopharmacol 2004;15(1):51-57)

KEY WORDS : Quetiapine · Extrapyramidal symptoms · Efficacy · Safety.

서론

가^{10,11)}

chlorpromazine, haloperidol
(serotonin - dopamine antagonist)

11)

quetiapine (efficacy)
(safety) 가

대상 및 방법

1. 연구 대상

가

1)

20~30%

quetiapine

가

2)

quetiapine

10 - 13)

3)

(tardive dyskinesia)

가 (Brief Psychi-
atric Rating Scale : BPRS)¹⁴⁾ 가

가

8 ,

1980

clozapine
가⁴⁻⁶⁾

18 t -
(power) 85%

가^{7,8)}

clozapine

quetiapine 50

30% 가

65

가

risperidone, olanzapine, quetiapine, clozapine,
ziprasidone

4 (Diagnostic and Statistical Manual of
Mental Disorders. 4th ed. : DSM -)¹⁵⁾

quetiapine clozapine

65

가 dibenzothiazepine

clozapine . Quetiapine 1)

clozapine

Clinical Global Impression(CGI)¹⁶⁾ Severity of

2 (D₂ receptor) 가⁹⁾

가 4 BPRS 가 27

가

가 , 2)

Quetiapine haloperidol risperidone

, 3) 가 1 65 가 (1).
 1) HIV 가 , 7 , 3
 , 2) 가 53
 3) quetiapine
 , 4)
 , 5) , 6) clozapine quetiapine 48
 , 7) 48
 , 8) 4 quetiapine
 , 9) 14 cytochrome P450 8
 3A4 , 10) 4 4 300 mg 52
 , 11) tiapine 750 mg que-
 , 12) 2 quetiapine 25 mg 1 2 , 2 50 mg 1
 , 13) 120 2 , 3 100 mg 1 2 , 4 150 mg
 / , 100 / 1 2 . 4
 , 14) quetiapine
 가 que-
 tiapine 가
 , 15)
 16) 가 ,
 , 17) , 18) que-
 tiapine , 19)
 1
 가 , ,
 , ,
 , .
 66 (31 , 35) 가

2. 연구 방법

1) 치료 약물 투여

quetiapine 48
 quetiapine
 quetiapine 8
 300 mg 52
 750 mg que-
 1
 quetiapine 25 mg 1 2 , 2 50 mg 1
 2 , 3 100 mg 1 2 , 4 150 mg
 1 2 . 4
 quetiapine

Table 1. Demographic and clinical characteristics of schizophrenia patients (n=64)

Characteristics	
Age (years)	34.2 (10.4)
Sex (male : female)	31 : 33
Duration of illness (years)	8.1 (8.3)
Mean peak dose (mg/d)	525.0 (225.1)
Diagnosis (n, %)	
Schizophrenia, disorganized	2 (3.1)
Schizophrenia, paranoid	30 (46.9)
Schizophrenia, undifferentiated	23 (35.9)
Schizophrenia, residual	8 (12.5)
Schizophreniform disorder	1 (1.6)

Values represent mean (SD) or frequency (%)

Quetiapine

가
300 mg
(agitation) loraze-
pam(4 mg) ,
zolpidem(20 mg) ,
benztropin propranolol

가
가 0
, 0
SAS
0.05

2) 평가 방법

2, 4, 6,
8 BPRS 가
CGI Severity of Illness
가
Simpson - An-
gus Scale¹⁷⁾ Abnormal Involuntary Movement Scale
(AIMS)¹⁸⁾ 가
가가
가
가 , 8
가
가

3) 자료 분석

quetiapine
quetiapine 53
(Repeated Measure One
way ANOVA) 64
Last Observation Carried Forward
가
(BPRS total score, CGI Severity of Illness score)
t - 30%
BPRS
Simpson - Angus Scale AIMS

결 과

1. 항정신병 효능

8 quetiapine
BPRS
(F=41.5, =0.6, df=2.4, p<0.000)(1).
2
64 가
(2).
CGI Severity of Illness 8
quetiapine
2 (3).
64
(4).
가 BPRS 가 30%
quetiapine
2 12 (18.8%), 4




Figure 1. Change of BPRS total score in 53 schizophrenia patients who finished quetiapine treatment for 8 weeks (n=53) * : Repeated measure one-way ANOVA p<0.05 : BPRS total score significantly decreased compared to baseline for week 2 through week 8 (F=41.5, =0.6, df=2.4, p<0.000).




Figure 2. Change of BPRS total score (n=64) * : p<0.05 compared to endpoint by paired samples t-test (t=7.87, df=63, p<0.000 ; 95% C.I. : 9.42 - 16.09).




Figure 3. Change of CGI Severity of Illness score in 53 schizophrenia patients who finished quetiapine treatment for 8 weeks (n=53) *Repeated measure one-way ANOVA p<0.05 ; CGI Severity of Illness score significantly decreased compared to baseline for week 2 through week 8 (F=27.6, $\eta^2=0.54$, df=2.18, p<0.000).




Figure 4. Change of CGI Severity of Illness score (n=64) * : p<0.05 compared to endpoint by paired samples t-test (t=6.90, df=63, p<0.000 ; 95% C.I. : 0.75 - 1.37).

26 (40.6%), 6 37 (57.8%), 8 42 (65.6%)
 (5).
 5.5(±0.3) , 64
 25% BPRS 가 30%




Figure 5. Response Rate in 2 weeks, 4 weeks, 6 weeks, and 8 weeks that is reduction more than 30% of BPRS total score in 64 schizophrenia patients (n=64).




Figure 6. Change of Simpson-Angus scale score compared to baseline.

가 4 ,
 50% 6 .
 2. 안전성
 64 quetiapine
 6 (9.
 3%), 4 (6.3%), 3 (4.7%), 2
 (3.1%), 1 (1.6%) .
 4 ,
 1 , 1 .

Simpson - Angus Scale AIMS 가
 가 8
 (6, 7).
 64.7 kg 8 66.6 kg 가
 가 (p=0.01).
 quetiapine ,
 8

Quetiapine




Figure 7. Change of AIMS score compared to baseline.

고찰

quetiapine
 quetiapine
 가 quetiapine
 가
 quetiapine BPRS
 CGI Severity of Illness
 quetiapine
 가가
 Last Observation Carried Forward
 ward
 quetiapine
 BPRS, CGI
 Severity of Illness
 quetiapine
 가 2
 25% BPRS 가 30%
 가 4 , 50%
 6 . 8
 65.6% 가 risperi-

done 20% 20)
 , risperidone
 가
 risperidone, olanzapine
 가 60~70%¹⁹⁻²²⁾
 , quetiapine
 가 65.6% quetiapine
 pine 가
 quetiapine 525
 mg
 quetiapine 350 mg,¹⁰⁻¹³⁾
²³⁾ 782
 518.4 mg
²³⁾ 750 mg
 가 17.4%
 가
 600 mg
 1200 mg
²³⁾
 가
 Simpson -
 Angus 가 가 4.2%, AIMS
 가 7.5%
^{11,12)}
 64.7 kg 8 66.6 kg 2.9%
 가
 (p=0.01), 가가 1.9 kg
¹²⁾
 가가

quetiapine
 65
 가 12 18.5% 2000
 24) que-
 tiapine 36~64%
 가
 quetiapine
 25) quetiapine
 가
 quetiapine
 quetiapine

중심 단어 :

참고 문헌

- 1) Seeman P, Lee T, Chau-Wong M, Wong K. *Antipsychotic doses and neuroleptic/dopamine receptors. Nature* 1976;261:717-719.
- 2) Kane JM. *The current status of neuroleptic therapy. J Clin Psychiatry* 1989;50:322-328.
- 3) Van Putten T. *Why do schizophrenic patients refuse to take their drugs? Arch Gen Psychiatry* 1974;31:67-72.
- 4) 이홍식 · 이희상 · 남궁기 · 김찬형 · 최낙경 · 도정호 등. 치료 저항 정신분열증 환자에서의 clozapine 효과. *대한정신약물학회지* 1993;4:161-168.
- 5) Kane J, Honigfeld G, Singer J, Meltzer HY, Clozaril Collaborative Study Group. *Clozapine for the treatment-resistant schizophrenia: A double-blind comparison with chlorpromazine. Arch Gen Psychiatry* 1988;45:789-796.
- 6) Meltzer HY, Bastini B, Kwon KY, Ramirez LF, Burnett S, Sharpe J. *A prospective study of clozapine in treatment-resistant schizophrenic patients. Psychopharmacology (suppl)* 1989;99:67-72.
- 7) Juul-Povlsen VJ, Noring V, Fog R, Gerlach J. *Tolerability and therapeutic effect of clozapine: A retrospective investigation of*

- 216 patients treated with clozapine for up to 12 years. *Acta Psychiatr Scand* 1985;71:176-185.
- 8) Meltzer HY. *The role of serotonin in the mechanism of action of antipsychotic drugs: Dose 5-HT also have a role in the etiology of schizophrenia? Schizophr Res* 1989;2:212.
- 9) Seeman P. *Antipsychotic drugs, dopamine receptors, and schizophrenia. Clin Neurosci Res* 2001;1:53-60.
- 10) Arvanitis LA, Miller BG, and the Seroquel Trial 13 Study Group. *Multiple fixed doses of 'Seroquel' (Quetiapine) in patients with acute exacerbation of schizophrenia: a comparison with haloperidol and placebo. Biol Psychiatry* 1997;42:233-246.
- 11) Mullen J, Jibson MD, Sweitzer D, and the QUEST Study Group. *A comparison of the relative safety, efficacy, and tolerability of Quetiapine and Risperidone in outpatients with schizophrenia and other psychotic disorders: the Quetiapine experience with safety and tolerability (QUEST) study. Clin Ther* 2001;23:1839-1854.
- 12) Small JG, Hirsch SR, Arvanitis LA, Miller BG, Link CGG, and the Seroquel Study Group. *Quetiapine in patients with schizophrenia: a high- and low-dose double-blind comparison with placebo. Arch Gen Psychiatry* 1997;54:549-557.
- 13) Borison RL, Arvanitis LA, Miller BG, and the US Seroquel Study Group. *ICI 204,636, an atypical antipsychotic: efficacy and safety in a multicenter, placebo-controlled trial in patients with schizophrenia. J Clin Psychopharmacol* 1996;16:158-169.
- 14) Overall JE, Gorham DR. *The Brief Psychiatric Rating Scale (BPRS): Recent developments in ascertainment and scaling. Psychopharmacol Bull* 1988;24:97-99.
- 15) American Psychiatric Association. *Diagnostic and Statistical Manual of Mental Disorders, 4th ed, Washington DC. American Psychiatric Association;1994.*
- 16) Guy W. *Early Clinical Drug Evaluation (ECDEU), Assessment Manual for Psychopharmacology (Revised Edition). Rockville, Md: US Department of Health, Education and Welfare; 1976. p.218-222.*
- 17) Simpson GM, Angus JW. *A rating scale for extrapyramidal side effects. Acta Psychiatr Scand (suppl)* 1970;212:11-19.
- 18) Guy W. *AIMS: Abnormal involuntary movement scale. In ECDEU Assessment Manual for Psychopharmacology (Revised Edition). Rockville, Md: US Department of Health, Education and Welfare; 1976.*
- 19) Bondolfi G, Dufour H, Patris M, May JP, Billeter U, Eap CB, Baumann P, on Behalf of the Risperidone Study Group. *Risperidone versus clozapine in treatment-resistant chronic schizophrenia: a randomized double-blind study. Am J Psychiatry* 1998;155:499-504.
- 20) Tollefson GD, Beasley CM, Tran PV, Street JS, Krueger JA, Tamura RN, et al. *Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial. Am J Psychiatry* 1997;154: 457-465.
- 21) Sanger TM, Liberman JA, Tohen M, Grundy S, Beasley C, Tollefson GD. *Olanzapine versus haloperidol treatment in first-episode psychosis. Am J Psychiatry* 1999;156:79-87.
- 22) Wirshing DA, Marshall BD, Green MF, Mintz J, Marder SR, Wirshing WC. *Risperidone in treatment-refractory schizophrenia. Am J Psychiatry* 1999;156:1374-1379.
- 23) Citrome L, Volavka J. *Optimizing dosing of atypical antipsychotics in adults: a review of the current evidence. Harvard Rev Psychiatry* 2002;10:280-291.
- 24) Srisurapanont M, Disayavanish C, Taimkaew K. *Quetiapine for schizophrenia (Cochrane review). The Cochrane Library, Issue 3; 2003. Oxford.*
- 25) Cutler AJ, Goldstein JM, Tumas JA. *Dosing and switching strategies for quetiapine fumarate. Clin Ther* 2002;24:209-222.